Nuclear Medicine and Biology
Volume 33, Issue 1 , Pages 37-42 , January 2006

Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism

  • Nobuyoshi Fukumitsu

      Affiliations

    • Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaragi 305-8575, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 29 853 7100; fax: +81 29 853 7102.
    • ,
  • Masahiko Suzuki

      Affiliations

    • Department of Neurology, The Jikei University School of Medicine, Tokyo 105-8461, Japan
    • ,
  • Takahiro Fukuda

      Affiliations

    • Department of Neuroscience, Research Center of Medical Science, The Jikei University School of Medicine, Tokyo 105-8461, Japan
    • ,
  • Yasushi Kiyono

      Affiliations

    • Radioisotope Research Laboratory, Kyoto University Hospital, Kyoto 606-8501, Japan
    • ,
  • Satomi Kajiyama

      Affiliations

    • Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8561, Japan
    • ,
  • Hideo Saji

      Affiliations

    • Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8561, Japan

Received 4 June 2005 ,Revised 24 July 2005 ,Accepted 26 July 2005.

References 

  1. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analogue. J Nucl Med. 1981;22:22–31
  2. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med. 1993;34:1140–1146
  3. Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of 123I-metaiodobenzyl guanidine in Parkinson's disease. Nucl Med Commun. 1998;19:137–142
  4. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:189–194
  5. Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med. 1999;40:371–375
  6. Linden D, Diehl RR, Berlit P. Sympathetic cardiovascular dysfunction in long-standing idiopathic Parkinson's disease. Clin Auton Res. 1997;7:311–314
  7. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol. 1997;38:2–7
  8. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol. 2003;2:669–676
  9. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology. 1999;53:1020–1025
  10. Takatsu H, Nagashima K, Murase M, Fujiwara H, Nishida H, Matsuo H, et al. Differentiation of Parkinson disease from multiple-system atrophy measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA. 2000;284:44–45
  11. Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med. 2000;27:566–573
  12. Hamada K, Hirayama M, Watanabe H, Kobayashi R, Ito H, Ieda T, et al. Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74:423–426
  13. Akincioglu C, Unlu M, Tunc T. Cardiac innervation and clinical correlates in idiopathic Parkinson's disease. Nucl Med Commun. 2003;24:267–271
  14. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in human due to a product of meperidine-analog synthesis. Science. 1982;219:979–980
  15. Burns RS, Vhiueh CC, Markey SP, Ebert MH, Javobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine. Proc Natl Acad Sci U S A. 1983;80:4546–4550
  16. Heikkila RE, Sonsalla PK. The MPTP-treated mouse as a model of parkinsonism: how good is it?. Neurochem Int. 1992;20(Suppl.):299S–303S
  17. Sundstrom E, Stromberg I, Tsutsumi T, Olson L, Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice. Comparison with three other strains of mice. Brain Res. 1987;405:26–38
  18. Sonsalla PK, Heikkila RE. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol. 1986;129:339–345
  19. Takatsu H, Nishida H, Matsuo H, Watanabe S, Nagashima K, Wada H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease — clinical and experimental studies with radiolabelled MIBG. J Nucl Med. 2000;41:71–77
  20. Yoshimura M, Komori T, Nakanishi T, Takanashi H. Estimation of sulphoconjugated catecholamine concentrations in plasma by high-performance liquid chromatography. Ann Clin Biochem. 1993;30:135–141
  21. Kiyono Y, Iida Y, Kawashima H, Tamaki N, Nishimura H, Saji H. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes. Eur J Nucl Med. 2001;28:894–899
  22. Kiyono Y, Iida Y, Kawashima H, Ogawa M, Tamaki N, Nishimura H, et al. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging. 2002;29:999–1005
  23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the Folin phenol reagent. J Biol Chem. 1951;193:265–275
  24. Hochberg Y, Tamhane AC. Multiple comparison procedures. New York: Wiley Series in Probability and Mathematical Statistics; 1987;
  25. Zigmond MJ, Stricker EM. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. In:  Smythies JR,  Bradley RJ editor. International review of neurobiology. vol. 31:San Diego: Academic Press; 1989;p. 10–79
  26. Gerlach M, Riederer P, Przuntek H, Youdim MB. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol. 1991;208:273–286
  27. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem. 1993;61:1191–1206
  28. Sundström E, Fredriksson A, Archer T. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res. 1990;528:181–188
  29. Zuddas A, Vaglini F, Fornai F, Corsini GU. Selective lesion of the nigrostriatal dopaminergic pathway by MPTP and acetaldehyde or diethyldithiocarbamate. Neurochem Int. 1992;20(Suppl.):287S–293S
  30. Fuller RW, Hahn RA, Snoddy HD, Wikel JH. Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol. 1984;33:2957–2960
  31. Ricaurte GA, Langston JW, Delanney LE, Irwin I, Peroutka SJ, Forno LS. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res. 1986;376:117–124
  32. Heikkila RE, Sieber BA, Manzino L, Sonsalla PK. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol. 1989;10:171–183
  33. Marien M, Briley M, Colpaert F. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur J Pharmacol. 1993;236:487–489
  34. Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon RO, Quyyumi AA, et al. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation. 1992;85:1775–1785
  35. Takatsu H, Wada H, Maekawa N, Takemura M, Saito K, Fujiwara H. Significant reduction of 125I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease. Nucl Med Commun. 2002;23:161–166
  36. Orimo S, Oka T, Miura H, Tsuchiya K, Mori F, Wakabayashi K, et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;73:776–777
  37. Orimo S, Ozawa E, Nakade S, Hattori H, Tsuchiya K, Taki K, et al. [123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease. Intern Med. 2003;42:127–128
  38. Date I, Felten DL, Felten SY. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 1990;519:266–276
  39. Kupsch A, Loschmann PA, Sauer H, Arnold G, Renner P, Pufal D, et al. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res. 1992;592:74–83

PII: S0969-8051(05)00198-8

doi: 10.1016/j.nucmedbio.2005.07.010

Nuclear Medicine and Biology
Volume 33, Issue 1 , Pages 37-42 , January 2006

Article Tools

* Image Usage & Resolution